Download the all-new Republic app:

Published 16:51 IST, July 19th 2020

COVID-19: In a first, India’s Case Fatality Rate falls below 2.5%, informs Health Ministry

In a significant development, India's Coronavirus fatality rate has fallen below 2.5% for the first time, the government said on Sunday

Reported by: Prachi Mankani
Follow: Google News Icon
  • share
null | Image: self
Advertisement

In a significant development, India's Coronavirus fatality rate has fallen below 2.5% for the first time, the government said on Sunday. India's total COVID cases rose to 1,077,618 of which 373,379 are active while 677,422 have recovered. 26,816 people have died so far.

"With effective containment strategy, aggressive testing and standardized clinical management protocols based on holistic Standard of Care approach, the Case Fatality Rate has significantly dipped. The Case Fatality Rate is progressively falling and currently, it is 2.49%. India has one of the lowest fatality rates in the world," the Ministry of Health and Family Welfare said.

Advertisement

The Ministry further stated that many states have conducted population surveys to map and identify the vulnerable population like the elderly, pregnant women and those with co-morbidities. The statement added that these surveys have ensured keeping the high-risk population under continuous observation, thus aiding early identification, timely clinical treatment and reducing fatalities

READ: COVID-recovered Delhi police personnel donate plasma at AIIMS; Union Health Min lauds them

Advertisement

READ: Coronavirus LIVE Updates: India's tally soars to 10,77,618; 1.37 crore samples tested

Seven Indian Pharma Players Race To Develop COVID-19 Vaccine

Meanwhile, at least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus that has already infected more than 14 million globally. Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.

Advertisement

Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within months because of the pandemic.

READ: Seven Indian pharma players race to develop COVID-19 vaccine

Advertisement

READ: Indiana reports 17 more COVID-19 deaths, 855 new cases

16:51 IST, July 19th 2020